PatternsRadar
Sign in

AUROPHARMAAurobindo Pharma Limited

NSEF&O
Full chart
1,692.80INR+17.90 (+1.07%)Close · 6 Oct 2026
5 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹97,400 CrMarket cap
26.2P/E (TTM)
62.7%Delivery

Filings & corporate actions

77 results filed
CSV
Next results · Q2 FY27
Expected 5 Nov 2026 – 12 Nov 2026
Estimate: filed 36–43 days after quarter end, last 5 times
Dividend
₹4.00 per share · last 8 Aug 2025
2026
  • 5 AugresultsResults · Q1 FY27 · consolidated and standalone-1.5%NSE
  • 15 JulshareholdingShareholding · 30 Jun 2026-0.2%NSE
  • 21 MayresultsResults · Q4 FY26 · consolidated and standalone-5.4%NSE
  • 17 AprshareholdingShareholding · 31 Mar 20260.0%NSE
  • 17 AprbuybackBuy Back0.0%
  • 9 FebresultsResults · Q3 FY26 · consolidated and standalone-6.6%NSE
  • 13 JanshareholdingShareholding · 31 Dec 2025-0.4%NSE

Reaction to results · all yearsrose on day 0 in 37 of 76 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY275 Aug 2026-1.5%+3.1%+1.5%1.4×
Q4 FY2621 May 2026-5.4%-7.3%-3.5%2.4×
Q3 FY269 Feb 2026-6.6%-1.4%+8.4%6.9×
Q2 FY265 Nov 2025-0.7%+5.3%+6.4%1.0×
Q1 FY264 Aug 2025-1.0%-3.0%-5.0%2.4×
Q4 FY2527 May 2025+0.9%-3.1%-6.5%2.4×
Q3 FY256 Feb 20250.0%-5.1%-8.3%1.4×
Q2 FY259 Nov 2024-2.9%-5.8%-7.7%4.1×
Q1 FY2510 Aug 2024+0.8%+6.0%+4.7%1.6×
Q4 FY2425 May 2024-3.1%-0.6%-1.4%2.9×
Q3 FY2410 Feb 2024+1.5%+3.8%+6.1%2.1×
Q2 FY2410 Nov 2023+3.0%+6.0%+5.6%3.0×
Q1 FY2412 Aug 2023+1.0%-2.4%+0.9%1.7×
Q4 FY2327 May 2023-0.6%+7.2%+17.3%3.1×
Q3 FY2310 Feb 2023+6.3%+7.3%+1.7%6.3×
Q2 FY2312 Nov 2022-0.4%-5.2%-7.8%4.6×
Q1 FY2312 Aug 2022+3.1%-4.2%-3.9%5.2×
Q4 FY2231 May 2022+1.9%-1.5%-3.1%1.9×
Q3 FY2210 Feb 2022+4.3%+2.8%-2.1%3.8×
Q2 FY229 Nov 2021+0.7%+2.2%+4.5%5.7×
Q1 FY2212 Aug 2021-7.9%-17.3%-9.5%13.4×
Q4 FY2131 May 2021-2.8%-2.6%-3.1%2.0×
Q3 FY2111 Feb 2021-3.4%-5.8%-12.4%1.7×
Q2 FY2112 Nov 2020+3.5%+2.8%+9.7%5.3×
Q1 FY2113 Aug 2020-5.7%-8.2%-14.1%2.6×
Q4 FY204 Jun 2020+1.2%+4.7%+3.9%3.0×
Q3 FY207 Feb 2020+7.1%+0.8%-7.7%5.1×
Q2 FY2013 Nov 2019-8.8%-1.0%+3.4%3.9×
Q1 FY208 Aug 2019+7.8%+8.9%+13.3%4.7×
Q4 FY1919 Jun 2019+2.4%0.0%-6.9%0.4×
Q3 FY1920 Feb 2019+2.1%+1.6%+8.5%1.0×
Q2 FY1926 Nov 2018+0.8%+1.9%-9.4%0.6×
Q1 FY1924 Aug 2018+1.6%+4.4%+11.4%1.3×
Q4 FY1826 Jun 2018+1.4%+2.9%-3.6%1.1×
Q3 FY1813 Mar 2018-0.2%-1.9%+5.0%0.7×
Q2 FY1811 Nov 2017-4.0%-4.5%-6.7%2.2×
Q1 FY1818 Aug 2017-1.2%+3.7%+6.3%0.6×
Q4 FY176 Jun 2017+2.2%+2.9%+16.8%0.7×
Q3 FY1711 Feb 2017-2.6%-1.5%-0.2%1.7×
Q2 FY1725 Nov 2016-0.5%-2.2%-15.7%0.7×
Q1 FY1729 Sept 2016+3.7%+3.7%-2.0%1.1×
Q4 FY1631 May 2016+4.1%+2.2%-3.2%2.6×
Q3 FY1611 Feb 2016+3.6%+2.6%+15.2%2.4×
Q2 FY167 Nov 2015+5.2%+2.1%-3.4%1.4×
Q1 FY1616 Aug 2015+2.8%-6.3%-6.4%1.2×
Q4 FY151 Jun 2015-1.0%-5.9%+2.1%0.5×
Q3 FY157 Feb 2015-5.5%-0.5%+1.7%1.7×
Q2 FY1511 Nov 2014+0.8%+11.8%+10.6%0.8×
Q1 FY1512 Aug 2014-0.8%+5.4%+16.7%0.9×
Q4 FY142 Jul 2014+2.5%-7.4%-2.7%1.1×
Q3 FY147 Feb 2014+2.8%-0.7%+2.9%2.1×
Q2 FY1422 Nov 2013+1.2%+6.7%+37.3%0.6×
Q1 FY1416 Aug 2013-1.3%-1.8%-4.6%0.8×
Q4 FY133 Jul 2013-0.6%+3.1%-8.9%0.6×
Q3 FY138 Feb 2013-1.5%-1.0%-11.6%1.5×
Q2 FY139 Nov 2012-4.7%-2.1%+7.2%2.8×
Q1 FY138 Aug 2012-1.7%-7.1%+10.1%3.4×
Q4 FY1230 May 2012-2.0%-1.1%-2.4%1.2×
Q3 FY1214 Feb 2012+7.9%+4.1%+7.1%2.5×
Q2 FY128 Nov 2011-3.4%-30.8%-27.0%5.1×
Q1 FY128 Aug 2011-3.0%-10.2%-16.1%1.2×
Q3 FY115 Feb 2011-1.4%-0.6%-21.0%2.3×
Q2 FY113 Nov 2010+1.8%+6.3%+4.3%5.6×
Q1 FY115 Aug 2010-4.4%-2.7%+6.3%3.0×
Q3 FY1030 Jan 2010+5.8%+4.3%+9.5%1.5×
Q2 FY1030 Oct 20090.0%+6.6%+15.0%1.1×
Q1 FY1031 Jul 2009+3.7%+6.5%+23.8%1.4×
Q4 FY0930 Apr 2009+10.3%+36.2%+80.5%2.5×
Q3 FY0930 Jan 2009-6.3%-11.3%-2.2%2.3×
Q2 FY0931 Oct 2008+4.0%+7.6%-11.6%3.0×
Q1 FY0930 Jul 2008+0.2%+8.7%+11.2%1.2×
Q4 FY0818 Jun 2008-5.0%-17.1%-20.6%3.4×
Q3 FY0830 Jan 2008-12.3%-18.2%-17.9%0.7×
Q2 FY0831 Oct 2007+2.0%-5.4%-14.5%1.4×
Q1 FY0831 Jul 2007-1.6%-4.9%-9.4%1.5×
Q4 FY071 Jul 2007-2.8%-8.0%-18.3%1.5×
Average-0.0%-0.4%+0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+16.3%
Profit YoY+25.2%
Interest cost YoY—
Revenue QoQ+3.4%
Profit QoQ+12.1%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open1,676.00
Day range1,670.90 – 1,694.70
52-week range1,066.80 – 1,740.00
From 52w high-2.7%
RSI (14)53.7
ATR (14)36.77
Volume10.10L
Avg volume (20D)8.29L
Rel volume1.22×
Volatility (1Y)25.9%
Turnover₹170.9Cr
SMA 50 / 2001,650.04 / 1,419.82

Delivery percentage

Latest · 6 Oct 202662.7%
20-day avg51.5%
1-year avg48.3%
Percentile (own history)97th
Range6.5–78.1%
Sessions1,731

Over the last 20 sessions AUROPHARMA settled 51.5% of its traded quantity, which is above average for an NSE equity. Its one-year average is 48.3%, so recent sessions are running 3.2 points higher than usual. The latest session ranks higher than 97% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.07%-0.28%+3.39%+6.93%+26.93%+55.30%

Valuation

CSV
Market cap₹97,400 Cr
P/E (TTM)26.2
EPS (TTM)64.49
Shares outstanding57.54Cr
Listed19 Jul 2000

Ownership

CSV
Promoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)8,285.78,645.98,853.39,150.4
YoY chg——+5.6%+16.3%
Net profit (₹ Cr)848.1909.8920.81,032.0
YoY chg——+2.0%+25.2%
Net margin10.2%10.5%10.4%11.3%
EPS14.6115.6715.8617.86

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 51.88% · public 48.12%
30 Sept 2021: promoter 51.83%31 Dec 2021: promoter 51.83%31 Mar 2022: promoter 51.83%30 Jun 2022: promoter 51.83%30 Sept 2022: promoter 51.83%31 Dec 2022: promoter 51.83%31 Mar 2023: promoter 51.83%30 Jun 2023: promoter 51.83%30 Sept 2023: promoter 51.83%31 Dec 2023: promoter 51.83%31 Mar 2024: promoter 51.83%30 Jun 2024: promoter 51.80%30 Sept 2024: promoter 51.82%31 Dec 2024: promoter 51.82%31 Mar 2025: promoter 51.82%30 Jun 2025: promoter 51.82%30 Sept 2025: promoter 51.82%31 Dec 2025: promoter 51.82%31 Mar 2026: promoter 51.82%30 Jun 2026: promoter 51.88%
2021-092026-06
  • Promoter
  • Public and others
Promoter
51.88%
Public
48.12%
Promoter change
+0.06 pp
Filed
15 Jul 2026
FII
16.38%
DII
25.10%
Promoter pledged
13.75%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue from operations7,219.47,351.87,580.27,567.07,796.17,978.58,382.17,868.18,285.78,645.98,853.39,150.4
Other income187.0162.5135.6220.9136.0157.3134.8105.3120.6187.6117.0264.2
Total income7,406.47,514.37,715.87,788.07,932.18,135.88,516.97,973.48,406.38,833.58,970.49,414.6
Total expenses6,331.76,249.36,351.16,462.76,724.96,937.67,149.76,768.67,132.07,430.17,677.37,857.8
└ Finance costs68.275.689.4111.0112.7118.5115.097.895.292.898.2101.7
└ Depreciation417.5423.3354.3404.2382.3418.5444.4405.7429.2464.7478.6486.8
Profit before tax1,074.71,265.01,242.61,325.31,207.21,198.31,367.31,204.91,274.31,338.21,293.01,516.6
Tax expense323.7322.5322.6405.7390.5354.3432.3382.6427.8428.7369.8483.1
Net profit751.9940.0907.4918.2817.0845.6902.8824.2848.1909.8920.81,032.0
EPS12.8316.0415.5115.6914.0014.5615.5614.2014.6115.6715.8617.86
Net margin10.42%12.79%11.97%12.13%10.48%10.60%10.77%10.48%10.24%10.52%10.40%11.28%
PBT margin14.89%17.21%16.39%17.51%15.48%15.02%16.31%15.31%15.38%15.48%14.61%16.57%
Tax rate30.12%25.49%25.96%30.61%32.35%29.57%31.61%31.75%33.57%32.04%28.60%31.85%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.

AUROPHARMA at a glance

  • AUROPHARMA closed at ₹1,692.8 on 6 Oct 2026, +1.07% on the day, +55.3% over one year, 2.7% below its 52-week high of ₹1,740.
  • Delivery was 62.7% of traded quantity on 6 Oct 2026, the 97th percentile of its own 1,731 sessions with a reading (20-session average 51.5%, 1-year average 48.3%).
  • Market capitalisation is ₹97,400 crore at a trailing P/E of 26.2 (trailing EPS ₹64.49).
  • Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹9,150 crore (+16.3% year on year), net profit ₹1,032 crore (+25.2%); the price moved -1.5% on the first session after.
  • Promoters held 51.88% at 30 Jun 2026, up 0.06 percentage points on the previous filing, with 13.75% of promoter shares pledged.
  • Q2 FY27 results are expected between 5 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE406A01037
SeriesEQ
Listed19 Jul 2000
History from19 Oct 1995
Sessions7,576
Turnover rank#221

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE